Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
General Information Job Advert Title: Senior Scientist, Discovery Formulation Location: Tsukuba, Ibaraki Division: Oncology Research Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to turning innovative science into VALUE for
JOB SUMMARY The Marketing and Communications Manager is part of an important team that creates and executes property-level communications to our customers. Under the leadership of the Director of Marketing and Communication, this role promotes on-brand
By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’s Privacy Notice and Terms
MV-22B Osprey experience preferred. LOCATION: MARINE CORPS AIR STATION FUTENMA, OKINAWA, JAPAN Assist Mechanic Is, IIs, and IIIs with performing organizational level maintenance while solving unusual maintenance problems by troubleshooting, testing, and repairing hydraulic, pneumatic, electronic,
General Information Job Advert Title: Manager/ Senior Researcher, DDS, Technology Scouting & Integration Labs. 主任研究員，DDS，技術統合研究所 Location: Tsukuba,Ibaraki or Yaizu, Shizuoka Division: Product Research & Development Employment Class: Permanent Description 【募集の背景 / Purpose & Scope】 DDS (drug
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)